公开(公告)号：US20230303540A1

公开(公告)日：2023-09-28

申请号：US18041849

申请日：2021-09-01

申请人： Merck Sharp & Dohme LLC

发明人： John J. Acton, III ,  Ryan Chau ,  Peter H. Fuller ,  Anmol Gulati ,  Rebecca Elizabeth Johnson ,  Solomon Kattar ,  Mitchell H. Keylor ,  Derun Li ,  Kaila A. Margrey ,  Gregori J. Morriello ,  Xin Yan

IPC分类号： C07D405/14 ,  C07D403/14 ,  C07D491/107 ,  C07D487/10 ,  C07D403/12 ,  C07D487/04 ,  C07D471/08 ,  C07D498/08 ,  C07D417/14

CPC分类号： C07D405/14 ,  C07D403/14 ,  C07D491/107 ,  C07D487/10 ,  C07D403/12 ,  C07D487/04 ,  C07D471/08 ,  C07D498/08 ,  C07D417/14

摘要： The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.